Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases

References

• Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A. 1978;75:285–288.
   PubMed Web of Science ®Google Scholar
• Lubini P, Zürcher W, Egli M. Stabilizing effects of the RNA 2ʹ-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2ʹ-O-methylated adenosines. Chem Biol. 1994;1:39–45.
   PubMed Web of Science ®Google Scholar
• Hudziak RM, Barofsky E, Barofsky DF, et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 1996;6:267–272.
   PubMedGoogle Scholar
• Geary RS, Yu RZ, Levin AA. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Invest Drugs. 2001;2:562–573.
   PubMedGoogle Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259‐293.
   PubMed Web of Science ®Google Scholar
• Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2013;9:169–182.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Carver K. Cellular uptake and intracellular trafficking of oligonucleotides. Adv Drug Deliv Rev. 2015;87:35–45.
   PubMed Web of Science ®Google Scholar
• Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44:6518–6548.
   PubMed Web of Science ®Google Scholar
• Lindow M, Vornlocher HP, Riley D, et al. Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat Biotechnol. 2012;30:920–923.
   PubMed Web of Science ®Google Scholar
• Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002;133:467–474.
   PubMed Web of Science ®Google Scholar
• Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14:9–21.
   PubMed Web of Science ®Google Scholar
• Scoles DR, Minikel EV, Stefan MP. Antisense oligonucleotides. A primer. Neurol Genet. 2019;5(2):e323.
   PubMed Web of Science ®Google Scholar
• Rossi JJ, Rossi D. Oligonucleotides and the COVID-19 pandemic: A perspective. Nucleic Acid Ther. 2020;30:129–132.
   PubMed Web of Science ®Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595–605.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637–647.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017–3026.
   PubMed Web of Science ®Google Scholar
• Hammond SM, Hazell G, Shabanpoor F, et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A. 2016;113(39):10962–10967.
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature. 1998;391:806–811.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.
   PubMed Web of Science ®Google Scholar
• Solano EC, Kornbrust DJ, Beaudry A, et al. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014;24:258–266.
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Jacobson SG, Drack AV, et al., Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect. Nat Med. 25(2): 225–228. 2019.
   PubMed Web of Science ®Google Scholar
• Coppieters F, Lefever S, Leroy BP, et al. CEP290, a gene with many faces: mutation overview and presentation of CEP290base. Hum Mutat. 2010;31:1097–1108.
   PubMed Web of Science ®Google Scholar
• den Hollander AI, Koenekoop RK, Yzer S, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum Genet. 2006;79:556‐561.
   PubMed Web of Science ®Google Scholar
• Collin RW, den Hollander AI, van der Velde-visser SD, et al. Antisense oligonucleotide (AON)-based therapy for Leber congenital amaurosis caused by a frequent mutation in CEP290. Mol Ther Nucleic Acids. 2012;1:e14.
   PubMedGoogle Scholar
• Gerard X, Perrault I, Hanein S, et al. AON-mediated exon skipping restores ciliation in fibroblasts harboring the common Leber congenital amaurosis CEP290 mutation. Mol Ther Nucleic Acids. 2012;1:e29.
   PubMedGoogle Scholar
• Garanto A, Chung DC, Duijkers L, et al. In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery. Hum Mol Genet. 2016;25:2552‐2563.
   PubMed Web of Science ®Google Scholar
• Parfitt DA, Lane A, Ramsden CM, et al. Identification and correction of mechanisms underlying inherited blindness in human iPSC-derived optic cups. Cell Stem Cell. 2016;18:769‐781.
   PubMed Web of Science ®Google Scholar
• Dulla K, Aguila M, Lane A, et al. Splice-modulating oligonucleotide QR-110 restores CEP290 mRNA and function in human c.2991+1655A>G LCA10 models. Mol Ther Nucleic Acids. 2018;12:730‐740.
   PubMedGoogle Scholar
• Cehajic-Kapetanovic J, Xue K, Martinez-fernandez de la Camara C, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020;26:354–359.
   PubMed Web of Science ®Google Scholar
• Dryja TP, McGee TL, Hahn LB, et al. Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N Engl J Med. 1990;323:1302–1307.
   PubMed Web of Science ®Google Scholar
• Sung CH, Davenport CM, Hennessey JC, et al. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991;88:6481–6485.
   PubMed Web of Science ®Google Scholar
• Athanasiou D, Aguila M, Bellingham J, et al. The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res. 2018;62:1–23.
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Sudharsan R, Dufour VL, et al. Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector. Proc Natl Acad Sci U S A. 2018;115:E8547–E8556.
   PubMed Web of Science ®Google Scholar
• Murray SF, Jazayeri A, Matthes MT, et al. Allele-specific inhibition of rhodopsin with an antisense oligonucleotide slows photoreceptor cell degeneration. Invest Ophthalmol Vis Sci. 2015;56:6362‐6375.
   Web of Science ®Google Scholar
• Edwards A, Fishman GA, Anderson RJ, et al. Visual acuity and visual field impairment in Usher syndrome. Arch Ophthalmol. 1998;116:165–168.
   PubMed Web of Science ®Google Scholar
• Iannaccone A, Kritchevsky SB, Ciccarelli ML, et al. Kinetics of visual field loss in Usher syndrome Type II. Invest Ophthalmol Vis Sci. 2004;45:784–792.
   PubMed Web of Science ®Google Scholar
• Fishman GA, Bozbeyoglu S, Massof RW, et al. Natural course of visual field loss in patients with Type 2 Usher syndrome. Retina. 2007;27:601–608.
   PubMed Web of Science ®Google Scholar
• Espinos C, Millan JM, Beneyto M, et al. Epidemiology of usher syndrome in Valencia and Spain. Community Genet. 1998;1:223–228.
   PubMedGoogle Scholar
• van Wijk E, Pennings RJ, Te Brinke H, et al. Identification of 51 novel exons of the usher syndrome type 2A (USH2A) gene that encode multiple conserved functional domains and that are mutated in patients with usher syndrome type II. Am J Hum Genet. 2004;74:738–744.
   PubMed Web of Science ®Google Scholar
• Reiners J, Nagel-Wolfrum K, Jürgens K, et al. Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. Exp Eye Res. 2006;83:97–119.
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia G, Aparisi MJ, Jaijo T, et al. Mutational screening of the USH2A gene in Spanish USH patients reveals 23 novel pathogenic mutations. Orphanet J Rare Dis. 2011;6:65.
   PubMed Web of Science ®Google Scholar
• Bhattacharya G, Miller C, Kimberling WJ, et al. Localization and expression of usherin: a novel basement membrane protein defective in people with Usher’s syndrome type IIa. Hear Res. 2002;163:1–11.
   PubMed Web of Science ®Google Scholar
• Eudy JD, Weston MD, Yao S, et al. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science. 1998;280:1753–1757.
   PubMed Web of Science ®Google Scholar
• van Diepen H, Dulla K, Chan HL, et al. QR-421a, an antisense oligonucleotide, for the treatment of retinitis pigmentosa due to USH2A exon 13 mutations. IOVS. 2019;60(ARVO abstract). https://iovs.arvojournals.org/article.aspx?articleid=2743135.
   Google Scholar
• Hastings ML, Jones TA. Antisense oligonucleotides for the treatment of inner ear dysfunction. Neurotherapeutics. 2019;16(2):348‐359.
   PubMed Web of Science ®Google Scholar
• Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–860.
   PubMed Web of Science ®Google Scholar
• Xue K, Jolly JK, Barnard AR, et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med. 2018;24:1507–1512.
   PubMed Web of Science ®Google Scholar
• Fry LE, Patrício MI, Williams J, et al. Association of messenger RNA level with phenotype in patients with choroideremia: potential implications for gene therapy dose. JAMA Ophthalmol. 2019;138:128‐135.
   Web of Science ®Google Scholar
• Dooley SJ, McDougald DS, Fisher KJ, et al. Spliceosome-mediated Pre-mRNA trans-splicing can repair CEP290 mRNA. Mol Ther Nucleic Acids. 2018;12:294‐308.
   PubMedGoogle Scholar
• Berger A, Lorain S, Joséphine C, et al. Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa. Mol Ther. 2015;23:918‐930.
   PubMed Web of Science ®Google Scholar
• Maeder ML, Stefanidakis M, Wilson CJ, et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019;25:229–233.
   PubMed Web of Science ®Google Scholar
• Giannelli SG, Luoni M, Castoldi V, et al. Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery. Hum Mol Genet. 2018;27:761–779.
   PubMed Web of Science ®Google Scholar
• Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229–236.
   PubMed Web of Science ®Google Scholar
• Bauwens M, De Zaeytijd J, Weisschuh N, et al. An augmented ABCA4 screen targeting noncoding regions reveals a deep-intronic founder variant in Belgian Stargardt patients. Hum Mutat. 2015;36:39‐42.
   Web of Science ®Google Scholar
• Albert S, Garanto A, Sangermano R, et al. Identification and rescue of splice defects caused by two neighboring deep-intronic ABCA4 mutations underlying stargardt disease. Am J Hum Genet. 2018;102:517‐527.
   PubMed Web of Science ®Google Scholar
• Zernant J, Lee W, Nagasaki T, et al. Extremely hypomorphic and severe deep-intronic variants in the ABCA4 locus result in varying Stargardt disease phenotypes. Cold Spring Harb Mol Case Stud. 2018;4:a002733.
   PubMed Web of Science ®Google Scholar
• Sangermano R, Garanto A, Khan M, et al. Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotides. Genet Med. 2019;21:1751–1760.
   PubMed Web of Science ®Google Scholar
• van den Hurk JA, van de Pol DJ, Wissinger B, et al. Novel types of mutation in the choroideremia (CHM) gene: a full-length L1 insertion and an intronic mutation activating a cryptic exon. Hum Genet. 2003;113:268–275.
   PubMed Web of Science ®Google Scholar
• Garanto A, van der Velde-visser SD, Cremers FPM, et al. Antisense oligonucleotide-based splice correction of a deep-intronic mutation in CHM underlying choroideremia. Adv Exp Med Biol. 2018;1074:83–89.
   PubMed Web of Science ®Google Scholar
• Webb TR, Parfitt DA, Gardner JC, et al. Deep-intronic mutation in OFD1, identified by targeted genomic next-generation sequencing, causes a severe form of X-linked retinitis pigmentosa (RP23). Hum Mol Genet. 2012;21:3647–3654.
   PubMed Web of Science ®Google Scholar
• Slijkerman RW, Vaché C, Dona M, et al. Antisense oligonucleotide-based splice correction for USH2A-associated retinal degeneration caused by a frequent deep-intronic mutation. Mol Ther Nucleic Acids. 2016;5:e381.
   PubMedGoogle Scholar
• Khan AO, Becirovic E, Betz C, et al. A deep-intronic CLRN1 (USH3A) founder mutation generates an aberrant exon and underlies severe Usher syndrome on the Arabian Peninsula. Sci Rep. 2017;7:1411.
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science. 2004;306:1796–1799.
   PubMed Web of Science ®Google Scholar
• Merkle T, Merz S, Reautschnig P, et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat Biotechnol. 2019;37:133–138.
   PubMed Web of Science ®Google Scholar
• Vogel P, Stafforst T. Critical review on engineering deaminases for site-directed RNA editing. Curr Opin Biotechnol. 2019;55:74‐80.
   PubMed Web of Science ®Google Scholar
• Fry LE, Peddle CF, Barnard AR, et al. RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences. Int J Mol Sci. 2020;21:777.
   PubMed Web of Science ®Google Scholar
• Trapani I, Toriello E, de Simone S, et al. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum Mol Genet. 2015;24:6811–6825.
   PubMed Web of Science ®Google Scholar
• McClements ME, Barnard AR, Singh MS, et al. An AAV dual vector strategy ameliorates the stargardt phenotype in adult Abca4-/- mice. Hum Gene Ther. 2019;30:590–600.
   PubMed Web of Science ®Google Scholar